[1]胡亚莉,邱金清,韩立柱,等.基于通降和胃法与网络药理学方法探讨半夏-枳实-黄连干预慢性胃炎的作用机制[J].西部中医药,2023,36(07):31-38.[doi:10.12174/j.issn.2096-9600.2023.07.07]
　HU Yali,QIU Jinqing,HAN Lizhu,et al.The Intervention Effects of Banxia-Zhishi-Huanglian on Chronic Gastritis Based on Tongjiang Hewei Method and Network Pharmacology Method[J].Western Journal of Traditional Chinese Medicine,2023,36(07):31-38.[doi:10.12174/j.issn.2096-9600.2023.07.07]
点击复制

基于通降和胃法与网络药理学方法探讨半夏-枳实-黄连干预慢性胃炎的作用机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年07期
页码:
31-38
栏目:
出版日期:
2023-07-15

文章信息/Info

Title:
The Intervention Effects of Banxia-Zhishi-Huanglian on Chronic Gastritis Based on Tongjiang Hewei Method and Network Pharmacology Method
作者:
胡亚莉, 邱金清, 韩立柱, 纪明睿, 姜华东
陕西中医药大学，陕西 咸阳 712046
Author(s):
HU Yali, QIU Jinqing, HAN Lizhu, JI Mingrui, JIANG Huadong
Shaanxi University of Chinese Medicine, Xianyang 712046, China
关键词:
慢性胃炎; 通降和胃法; 半夏; 枳实; 黄连; 网络药理学; 分子对接; 作用机制
Keywords:
chronic gastritis; method; network pharmacology; molecular docking; mechanism
分类号:
R966
DOI:
10.12174/j.issn.2096-9600.2023.07.07
文献标志码:
A
摘要:
目的总结沈舒文教授通降和胃法辨治慢性胃炎（chronic gastritis，CG）的经验，基于网络药理学方法和分子对接技术对探讨半夏-枳实-黄连角药治疗CG平调寒热，升降气机的作用机制。 方法运用TCMSP、ETCM、BATMAN等数据库筛选半夏-枳实-黄连相关靶点，建立药物靶点数据库；通过CTD、DisGenet、GeneCards数据库筛选CG潜在靶点；利用Venny 2.1对药物靶点和疾病靶点进行映射，通过STRING平台构建交集靶点PPI网络；运用ClusterProfiler程序包进行基因本体（gene ontology，GO）功能富集分析和京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）富集分析；利用Cytoscape 3.7.0构建“药物-潜在靶标-信号通路”网络关系图；通过Discovery Studio 2016软件对核心药效物质和受体蛋白进行分子对接分析。 结果沈舒文教授应用半夏-枳实-黄连角药通过寒热平调通降法辨治CG寒热互结、胃失和降证，效果良好。筛选得到药物靶点黄连165个，半夏84个，枳实114个，CG潜在靶点324个。活性成分通过作用于诱导型前列腺素内过氧化物合酶（prostaglandin-endoperoxide synthase 2，PTGS2)、过氧化物酶体增生激活受体γ（peroxisome proliferative activated receptor gamma，PPARG）和B淋巴细胞瘤(B-cell lymphoma-2，Bcl-2)等80个靶点发挥作用；靶点主要通过对氧化合物反应、对脂质反应和活性氧代谢正调控等方面参与流体剪切应力和动脉粥样硬化、AGE-RAGE、白细胞介素17(interleukin-17，IL-17)等信号通路。活性成分与关键靶点之间结合具有良好的亲和力。 结论半夏-枳实-黄连角药中柚皮苷、β-谷甾醇、豆甾醇、异橙黄酮等活性成分通过PTGS2、PPARG和BCL-2等靶点作用于流体剪切应力和动脉粥样硬化、AGE-RAGE和IL-17等信号通路，通过多组分、多靶标、多通路发挥治疗CG的作用。
Abstract:
ObjectiveTo sum up professor Shen Shuwen's experience in differentiating and treating chronic gastritis (CG) by Tongjiang Hewei method, and discuss the mechanism of Banxia-Zhishi-Huanglian in the treatment of CG by mildly regulating cold and heat, adjusting Qi movement based on network pharmacology and molecular docking technology. MethodsTCMSP, ETCM and BATMAN databases were used to screen the targets related to Banxia-Zhishi-Huanglian, and to establish the data of herbal targets; CTD, DisGenet and GeneCards were used to screen the potential targets of CG; Venny 2.1 was applied to perform the mapping of herbal targets and disease targets, the intersection targets were used to build PPI network through STRING platform; ClusterProfiler software package was utilized to carry out enrichment analysis of GO function and KEGG pathway; Cytoscape 3.7.0 was used to construct the network diagram of “medicine-potential targets-signal pathway”; molecular docking analysis of the core pharmacodynamic substances and receptor protein was performed using Discovery Studio 2016 software. ResultsProfessor Shen Shuwen applied the method of mildly regulating cold and heat, adjusting Qi movement to differentiate and treat CG of intermingling cold with heat, stomach Qi rising with the good effects of Banxia-Zhishi-Huanglian. By screening, 165 Huanglian targets, 84 Banxia ones, 114 Zhishi ones and 324 CG potential targets were yielded. The active ingredients could play a role through acting on 80 targets including PTGS2, PPARG and Bcl-2; the targets, mainly involving the reaction to the oxygen compounds, lipid response and positive regulation of reactive oxygen species metabolism, participate in signal pathway such as fluid shear stress and atherosclerosis, AGE-RAGE, and interleukin 17 (IL-17). Binding between the active ingredients and key targets have good affinity. ConclusionThe active ingredients such as Naringin, β-sitosterol, myristerol and isoorange flavonoids contained in Banxia-Zhishi-Huanglian act on signal pathways including fluid shear stress and atherosclerosis, AGE-RAGE, and IL-17, which could play a role in treating CG through many components, many targets and pathways.

相似文献/References:

[1]骆元斌,顾立萍,黄小玲△.胃黄色瘤30例临床病理分析[J].西部中医药,2013,26(01):119.
　LUO Yuanbin,GU Liping,HUANG Xiaoling.Pathological Analysis for 30 Cases of Gastric Xanthoma[J].Western Journal of Traditional Chinese Medicine,2013,26(07):119.
[2]陈燕云,指导：王自立.中医药治疗慢性萎缩性胃炎的研究进展[J].西部中医药,2013,26(04):123.
　CHEN Yanyun Director: WANG Zili.Research Progress on the Treatment of Chronic Atrophic Gastritis with TCM[J].Western Journal of Traditional Chinese Medicine,2013,26(07):123.
[3]金娟,张志明,雍文兴,等.中医药对慢性胃炎病机认识及诊治的研究进展[J].西部中医药,2022,35(02):157.[doi:10.12174/j.issn.2096-9600.2022.02.40]
　JIN Juan,ZHANG Zhiming,YONG Wenxing,et al.Research Progress on the Pathogenesis, Diagnosis and Treatment of Chronic Gastritis in Traditional Chinese Medicine[J].Western Journal of Traditional Chinese Medicine,2022,35(07):157.[doi:10.12174/j.issn.2096-9600.2022.02.40]
[4]伊力范江·库尔班,阿提坎木·瓦合甫,买买提依力·努尔买提,等.慢性胃炎的维吾尔医证候分布规律研究[J].西部中医药,2023,36(09):83.[doi:10.12174/j.issn.2096-9600.2023.09.18]
　Yilifanjiang· KUERBAN,Atikanmu· WAHEFU,Maimaitiyili· NUERMAITI,et al.Study on the Distribution Rules of Uygur Syndrome of Chronic Gastritis[J].Western Journal of Traditional Chinese Medicine,2023,36(07):83.[doi:10.12174/j.issn.2096-9600.2023.09.18]

备注/Memo

备注/Memo:
胡亚莉（1978—），女，硕士学位，副教授。研究方向：中医药治疗脾胃病的临床与基础研究。第六批全国老中医药专家学术经验继承工作项目（国中医药人教发［2017］29号）；咸阳市二0二0重点研发计划（2020k02-113）；陕西中医药大学慢性食疗营养与养生创新团队项目（2019-py01）。
更新日期/Last Update: 2023-07-15